Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Kater, Arnon P ; Levin, Mark-David ; Niemann, Carsten U. / Ibrutinib and Venetoclax for First-Line Treatment of CLL. I: The New England journal of medicine. 2019 ; Bind 381, Nr. 8. s. 788-789.

Bibtex

@article{510f3c78159b47e4be37c1c884eeffdb,
title = "Ibrutinib and Venetoclax for First-Line Treatment of CLL",
keywords = "Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Pyrazoles, Pyrimidines, Sulfonamides",
author = "Kater, {Arnon P} and Mark-David Levin and Niemann, {Carsten U}",
year = "2019",
month = "8",
day = "22",
doi = "10.1056/NEJMc1908754",
language = "English",
volume = "381",
pages = "788--789",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "8",

}

RIS

TY - JOUR

T1 - Ibrutinib and Venetoclax for First-Line Treatment of CLL

AU - Kater, Arnon P

AU - Levin, Mark-David

AU - Niemann, Carsten U

PY - 2019/8/22

Y1 - 2019/8/22

KW - Bridged Bicyclo Compounds, Heterocyclic

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Pyrazoles

KW - Pyrimidines

KW - Sulfonamides

U2 - 10.1056/NEJMc1908754

DO - 10.1056/NEJMc1908754

M3 - Journal article

VL - 381

SP - 788

EP - 789

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 8

ER -

ID: 58442118